Display options
Cite
Timofeev J, Ruiz G, Fries M, et al. Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy. AJP Rep. 2013;3(2):71-4doi: 10.1055/s-0033-1338169.
Timofeev, J., Ruiz, G., Fries, M., & Driggers, R. W. (2013). Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy. AJP reports, 3(2), 71-4. https://doi.org/10.1055/s-0033-1338169
Timofeev, Julia, et al. "Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy." AJP reports vol. 3,2 (2013): 71-4. doi: https://doi.org/10.1055/s-0033-1338169
Timofeev J, Ruiz G, Fries M, Driggers RW. Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy. AJP Rep. 2013 Oct;3(2):71-4. doi: 10.1055/s-0033-1338169. Epub 2013 Mar 18. PMID: 24147238; PMCID: PMC3799704.
Copy Download .nbib Format: NLM
Share it on

AJP Rep. 2013 Oct;3(2):71-4. doi: 10.1055/s-0033-1338169. Epub 2013 Mar 18.

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy.

AJP reports

Julia Timofeev, George Ruiz, Melissa Fries, Rita W Driggers

Affiliations

  1. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, MedStar Health, Washington, District of Columbia.

PMID: 24147238 PMCID: PMC3799704 DOI: 10.1055/s-0033-1338169

Abstract

Background Pulmonary arterial hypertension carries a high risk of mortality in pregnancy. Recent advances in treatment may improve disease course and allow for successful management of the pregnancy. Case Report We present the case of a 20-year-old gravida 1, para 0 with diagnosis of severe primary pulmonary hypertension. The patient was managed with epoprostenol (prostacyclin) infusion via an indwelling catheter, which was initiated at 23 weeks' gestation. The dose was adjusted to the patient's symptoms and a successful vaginal delivery was achieved at 36 weeks' gestation. Although maternal postpartum course was uncomplicated, unexplained neonatal demise occurred at 11 days of life. Conclusion Successful management of pulmonary hypertension in pregnancy can be accomplished with a multidisciplinary approach and intensive therapy. Long-term effects of epoprostenol on fetal or neonatal well-being are unknown.

Keywords: epoprostenol; prostacyclin; prostaglandin; pulmonary hypertension

References

  1. J Am Coll Cardiol. 1998 Jun;31(7):1650-7 - PubMed
  2. N Engl J Med. 2004 Sep 30;351(14):1425-36 - PubMed
  3. Obstet Gynecol. 2004 May;103(5 Pt 2):1102-5 - PubMed
  4. Obstet Gynecol. 2005 Nov;106(5 Pt 2):1206-10 - PubMed
  5. Am J Obstet Gynecol. 1989 Apr;160(4):871-6; discussion 876-8 - PubMed
  6. Int J Obstet Anesth. 2009 Apr;18(2):156-64 - PubMed
  7. Treat Respir Med. 2004;3(1):29-34 - PubMed
  8. Eur Heart J. 2009 Feb;30(3):256-65 - PubMed

Publication Types